Patents by Inventor Timothy N. C. Wells

Timothy N. C. Wells has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uses of a chemokine receptor able to bind to MCP-1, MIP-1? and/or RANTES
    Patent number: 7655425
    Abstract: A chemokine receptor binds to MCP-1, MIP-1? and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1? and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: February 2, 2010
    Assignee: Glaxo Group Limited
    Inventors: Timothy N. C. Wells, Christine A. Power
  • Chemokine mutants in the treatment of multiple sclerosis
    Patent number: 7402303
    Abstract: Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: July 22, 2008
    Assignee: Laboratoires Serono SA
    Inventors: Amanda Proudfoot, Timothy N. C. Wells, Marie Kosco-Vilbois
  • Chemokine receptor able to bind to MCP-1, MIP-1 ? and/or rantes and its uses
    Patent number: 7183063
    Abstract: A chemokine receptor binds to MCP-1, MIP-1? and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1? and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: February 27, 2007
    Assignee: Glaxo Group Limited
    Inventors: Timothy N. C. Wells, Christine A. Power
  • Substances and their uses
    Patent number: 6919432
    Abstract: A chemokine receptor binds to MCP-1, MIP-1? and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1? and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: July 19, 2005
    Assignee: Glaxo Group Limited
    Inventors: Timothy N. C. Wells, Christine A. Power
  • Chemokine receptor antagonist and cyclosporin in combined therapy
    Patent number: 6902728
    Abstract: The use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells is herein disclosed. Said pharmaceutical compositions for the simultaneous, sepatate or sequential use of its active ingredients for the above specified therapy are also disclosed and claimed. In particular, the use of Met-RANTES together with cyclosporin A to produce a pharmaceutical composition for the treatment of renal allograft transplant rejection is experimentally shown.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: June 7, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Hermann-Joseph Grone, Peter J. Nelson, Amanda Proudfoot, Timothy N. C. Wells
  • Chemokine mutants in the treatment of multiple sclerosis
    Publication number: 20040101509
    Abstract: Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.
    Type: Application
    Filed: November 13, 2003
    Publication date: May 27, 2004
    Inventors: Amanda Proudfoot, Timothy N.C. Wells, Marie Kosco-Vilbois
  • Method of treatment with a RANTES antagonist polypeptide
    Patent number: 6555105
    Abstract: Modifications to RANTES can result in the modified polypeptide acting as a RANTES or MIP-1&agr; antagonist. Such antagonists can be used in therapy to reduce inflammation. They are also useful in studying the properties of RANTES or of MIP-1&agr;.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: April 29, 2003
    Assignee: Glaxo Group Limited
    Inventors: Amanda E. I. Proudfoot, Timothy N. C. Wells
  • Substances and their uses
    Publication number: 20020187930
    Abstract: A chemokine receptor binds to MCP-1, MIP-1&agr; and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1&agr; and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.
    Type: Application
    Filed: January 19, 2001
    Publication date: December 12, 2002
    Applicant: GLAXO GROUP LIMITED
    Inventors: Timothy N. C. Wells, Christine A. Power
  • Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
    Publication number: 20020160015
    Abstract: A chemokine receptor binds to MCP-1, MIP-1&agr; and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1&agr; and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.
    Type: Application
    Filed: April 12, 2002
    Publication date: October 31, 2002
    Applicant: GLAXO GROUP LIMITED
    Inventors: Timothy N.C. Wells, Christine A. Power
  • DNA encoding rantes peptide fragments and methods of treatment with the fragments
    Patent number: 6159711
    Abstract: Modifications to RANTES can result in the modified polypeptide acting as a RANTES or MIP-1.alpha. antagonist. Such antagonists can be used in therapy to reduce inflammation. They are also useful in studying the properties of RANTES or of MIP-1.alpha..
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: December 12, 2000
    Assignee: Glaxo Group Limited
    Inventors: Amanda E. I. Proudfoot, Timothy N. C. Wells
  • Chemokine receptor able to bind to MCP-1, MIP-1.alpha. and/or RANTES. Its uses
    Patent number: 6150132
    Abstract: A chemokine receptor binds to MCP-1, MIP-1.alpha. and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1.alpha. and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: November 21, 2000
    Assignee: Glaxo Group Limited
    Inventors: Timothy N. C. Wells, Christine A. Power